Q32 Bio (FRA:DB0) PS Ratio: 3.12 (As of Jul. 07, 2026) — 128% Above Median


FRA:DB0 Q32 Bio Inc FRA:DB0
17 GF Score
Price €11.33
! 6 Warning Signs
View Full Analysis

What is Q32 Bio PS Ratio?

Q32 Bio FRA:DB0 -0.18% 17 PS Ratio is 3.12 as of Jul. 07, 2026, which is 128% above its 10-year median of 1.37. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 929 Biotechnology companies, Q32 Bio ranks better than 77.29% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Q32 Bio's share price is €11.33. Q32 Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.64. Hence, Q32 Bio's PS Ratio for today is 3.12.

Warning Sign:

Q32 Bio Inc stock PS Ratio (=3.02) is close to 1-year high of 3.09.

The historical rank and industry rank for Q32 Bio's PS Ratio or its related term are showing as below:

FRA:DB0' s PS Ratio Range Over the Past 10 Years
Min: 0.81   Med: 1.37   Max: 3.09
Current: 3.02

During the past 5 years, Q32 Bio's highest PS Ratio was 3.09. The lowest was 0.81. And the median was 1.37.

FRA:DB0's PS Ratio is ranked better than
77.29% of 929 companies
in the Biotechnology industry
Industry Median: 9.64 vs FRA:DB0: 3.02

Q32 Bio's Revenue per Sharefor the three months ended in Mar. 2026 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.64.

During the past 3 years, the average Revenue per Share Growth Rate was 98.50% per year.

During the past 5 years, Q32 Bio's highest 3-Year average Revenue per Share Growth Rate was 98.50% per year. The lowest was 98.50% per year. And the median was 98.50% per year.

Back to Basics: PS Ratio


Q32 Bio  (FRA:DB0) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Q32 Bio PS Ratio Related Terms


Q32 Bio PS Ratio Historical Data

* Premium members only.

The historical data trend for Q32 Bio's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio PS Ratio Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
0.00 0.00 0.00 0.00 0.76

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.76 1.51

FRA:DB0 vs CAMP, CDXS, KROS: PS Ratio Comparison

For the Biotechnology subindustry, Q32 Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's PS Ratio distribution charts can be found below:

* The bar in red indicates where Q32 Bio's PS Ratio falls into.


FRA:DB0
17GF Score
Q32 Bio Inc FRA:DB0
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Q32 Bio's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=11.33/3.636
=3.12

Q32 Bio's Share Price of today is €11.33.
Q32 Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.64.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 3.12 mean?
Q32 Bio (FRA:DB0) has a PS Ratio of 3.12 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Q32 Bio and its competitors. This is 128% above median its historical median of 1.37. Over the past decade, Q32 Bio's PS Ratio has ranged from 0.81 to 3.09. According to the industry distribution chart, Q32 Bio ranks #211 out of 929 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Q32 Bio's PS Ratio too high?
Q32 Bio's current PS Ratio of 3.12 is 128% above median its 10-year median of 1.37. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 3.09. The Biotechnology industry median PS Ratio is 9.64. Q32 Bio's value of 3.12 is 67.6% below this industry median. Based on the distribution chart, Q32 Bio ranks #211 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's PS Ratio compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #211 out of 929 companies for PS Ratio. This places Q32 Bio in the top 23% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.64. Q32 Bio's value of 3.12 is 67.6% below this benchmark. Historically, Q32 Bio's own PS Ratio has ranged from 0.81 to 3.09 over the past decade. While the company's 10-year median is 1.37 vs. the industry median of 9.64, Q32 Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q32 Bio's current PS Ratio of 3.12 is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Q32 Bio and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current PS Ratio is 3.12, which is 128% above median its own 10-year median of 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current PS Ratio of 3.12. The current PS Ratio is 3.12, which is 128% above median its 10-year median of 1.37 and 67.6% below the Biotechnology industry median of 9.64. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current PS Ratio is 3.12 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USA
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for FRA:DB0

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.33
Price